ArriVent BioPharma (AVBP) Share-based Compensation (2023 - 2026)
ArriVent BioPharma (AVBP) posted Share-based Compensation of $82.0 million for Q1 2026, up 2445.0% sequentially from $3.2 million in Q4 2025, and up 3510.74% YoY from $2.3 million in Q1 2025.
ArriVent BioPharma (AVBP) Share-based Compensation (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Share-based Compensation for 4 years, with the latest figure at $82.0 million in Q1 2026.
- Quarterly Share-based Compensation rose 3510.74% year-over-year to $82.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82.0 million (up 1589.68% YoY) and the FY2025 annual result came in at $37.6 million, up 295.79% from the prior year.
- Share-based Compensation rose to $82.0 million in Q1 2026 per AVBP's latest filing, from $3.2 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $216.0 million in Q3 2023 and troughed at $166000.0 in Q1 2023.
- A 4-year average of $39.0 million and a median of $2.3 million in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation slumped 99.6% in 2024, then jumped 3510.74% in 2026.
- Over 4 years, Share-based Compensation stood at $319000.0 in 2023, then surged by 198.12% to $951000.0 in 2024, then soared by 238.8% to $3.2 million in 2025, then jumped by 2445.0% to $82.0 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $82.0 million, $3.2 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 79.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.50 Mn |
| Jun 30, 2026 | 79.50 Mn |
| Mar 31, 2026 | 82.00 Mn |
| Mar 31, 2026 | 82.00 Mn |
| Dec 31, 2025 | 3.22 Mn |
| Dec 31, 2025 | 3.22 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Dec 31, 2024 | 951,000.00 |
| Dec 31, 2024 | 951,000.00 |
| Sep 30, 2024 | 865,000.00 |
| Sep 30, 2024 | 865,000.00 |
| Jun 30, 2024 | 766,000.00 |
| Jun 30, 2024 | 766,000.00 |
| Mar 31, 2024 | 625,000.00 |
| Mar 31, 2024 | 625,000.00 |